# Trio Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/trio-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: San Francisco, US
- Website: www.triopharmaceuticals.com
- Total disclosed funding: $4.6M
- Latest round: Series A (Dec 3, 2024)
- Investors on record: 5

## About

Based in California, US, and founded in 2018 by its CEO Reiner Laus, and COO Shiva Bhowmik, Trio Pharmaceuticals Inc. operates as a cancer immunotherapeutics company that specializes in developing dual-action drugs to generate immunogenic tumors. In December 2024, Trio Pharmaceuticals Inc. raised USD 3.1 million in pre-series A funding led by returning investor Friedman Bioventures, with participation from new investors Myeloma Investment Fund and Life Science Angels, Inc. Another returning investor NuFund Venture Group and other unspecified investors also participated in the round. Trio Pharmaceuticals Inc. offers a platform of dual-action tumor immunity-enhancing drugs targets specific antigens on cancer cells and immunosuppressor cells, selectively stopping tumor growth and immunosuppression in the tumor without targeting the immune checkpoint pathways.

## Funding rounds

- Series A, Dec 3, 2024, $3.1M — Life Science Angels, Inc., Friedman Bioventures, Myeloma Investment Fund, NuFund Venture Group
- Seed, Nov 1, 2022, $1.5M — Friedman Bioventures, SeedFolio, NuFund Venture Group

## Investors

- Friedman Bioventures (https://capitalatlas.ai/funds/friedman-bioventures) — Seed, Series A
- SeedFolio (https://capitalatlas.ai/funds/seedfolio) — Seed
- NuFund Venture Group (https://capitalatlas.ai/funds/nufund-venture-group) — Seed, Series A
- Life Science Angels, Inc. — Series A
- Myeloma Investment Fund (https://capitalatlas.ai/funds/myeloma-investment-fund) — Series A